MARKET

SPTX

SPTX

SEAPORT THERAPEUTICS INC
NASDAQ
23.28
+1.53
+7.03%
Closed 19:30 09/10 EDT
OPEN
21.58
PREV CLOSE
21.75
HIGH
23.28
LOW
21.58
VOLUME
144.71K
TURNOVER
--
52 WEEK HIGH
28.38
52 WEEK LOW
14.85
MARKET CAP
1.25B
P/E (TTM)
-14.1219
1D
5D
1M
3M
1Y
5Y
1D
Analysts Conflicted on These NA Names: SailPoint, Inc. (SAIL) and Seaport Therapeutics, Inc. (SPTX)
TipRanks · 22h ago
Citi Keeps Their Buy Rating on Seaport Therapeutics, Inc. (SPTX)
TipRanks · 22h ago
Analysts Offer Insights on NA Companies: Seaport Therapeutics, Inc. (SPTX), Navan, Inc. Class A (NAVN) and International Business Machines (IBM)
TipRanks · 1d ago
Seaport Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
Benzinga · 1d ago
Seaport Reports Positive GlyphAllo Driving Trial Results In Healthy Volunteers
NASDAQ · 2d ago
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Barchart · 2d ago
Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint
Benzinga · 2d ago
More
About SPTX
Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. It is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.

Webull offers Seaport Therapeutics stock information, including NASDAQ: SPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPTX stock methods without spending real money on the virtual paper trading platform.